Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CD38 monoclonal antibody CID-103

A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the cell surface glycoprotein ADP-ribosyl cyclase 1 (CD38), with potential antineoplastic activity. Upon administration, anti-CD38 monoclonal antibody CID-103 specifically targets and binds to CD38 expressed on tumor cells. This may trigger antibody-dependent cellular cytotoxicity (ADCC), cell lysis and depletion of CD38-expressing tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Code name:	CID 103 CID-103 CID103 TSK011010

anti-CD38 monoclonal antibody CID-103

Search NCI's Drug Dictionary